创模生物科技(北京)有限公司

CN / En

NEWS

Immuno-co-culture killing model platform by InnoModels Biotechnology

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-21 15:51
  • Views:

(Summary description)In the field of life sciences and pharmaceutical research and development, innovation is the key to driving technological advancement and disease treatment. InnoModels Biotechnology (Beijing), as a leader in this field, has provided strong support for cancer treatment and immunotherapy research through its innovative immunoco-culture killing model platform. In this article, we will introduce this platform in detail and discuss its important role in research and clinical applications.

Immuno-co-culture killing model platform by InnoModels Biotechnology

(Summary description)In the field of life sciences and pharmaceutical research and development, innovation is the key to driving technological advancement and disease treatment. InnoModels Biotechnology (Beijing), as a leader in this field, has provided strong support for cancer treatment and immunotherapy research through its innovative immunoco-culture killing model platform. In this article, we will introduce this platform in detail and discuss its important role in research and clinical applications.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-21 15:51
  • Views:
Information

In the field of life sciences and pharmaceutical research and development, innovation is the key to driving technological advancement and disease treatment. InnoModels Biotechnology (Beijing), as a leader in this field, has provided strong support for cancer treatment and immunotherapy research through its innovative immunoco-culture killing model platform. In this article, we will introduce this platform in detail and discuss its important role in research and clinical applications.
Background and Establishment of the Platform
Ltd. was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and the Institute of Immunology of Shanghai Jiao Tong University. Since its establishment, the company has been focusing on oncology and tumor immunopharmacodynamics CRO services, translational medicine research services and individualized medicine, and is committed to providing a new generation of experimental animal models close to the clinic. Its immune co-culture killing model platform is an important technological breakthrough in this direction.
Platform Features and Technical Advantages
1. Precise cell culture technology
Through advanced cell culture technology, the immune co-culture killing model constructs a more realistic three-dimensional tissue structure, simulating the complex interaction between immune cells and tumor cells in the body. This model not only improves the biological realism of experiments, but also enables researchers to more accurately predict the effects of therapeutic drugs in the body.
2. Introduction of multiple cell types
Unlike traditional immune models, this model is able to introduce multiple immune cell types at the same time, such as natural killer cells (NK cells) and T cells. The introduction of multiple cell types makes the simulated immune response process more complex and closer to the real situation, and the experimental results are more biologically meaningful.
3. Advanced Microscopy and Imaging Analysis
The platform uses advanced microscopy technology and imaging analysis to provide real-time observation at the cellular level. This visualization feature enables researchers to intuitively observe the killing process of immune cells and gain a deeper understanding of the mechanism of immunotherapy.
4. Exhaustive biomarker analysis
The model allows detailed analysis of biomarkers in the immune response, helping researchers to discover potential predictive indicators that provide an important basis for clinical research and the design of therapeutic regimens.

 


Application Areas and Impact
1. Cancer therapeutic research
The immune co-culture killing model has a wide range of applications in cancer therapy research. It can efficiently and accurately assess the immuno-killing effect of potential therapeutic drugs, optimize the engineering of immune cells, and improve their recognition and killing ability of tumor cells. In addition, based on a patient's immune profile, the platform can customize treatment plans and improve the individualization of treatment.
2. Drug Screening and Evaluation
The platform can be used for large-scale drug screening to assess the killing effect and toxicity level of drugs on cells, providing important data for safety assessment during drug development. This efficient screening mechanism helps to shorten the cycle of new drug development and reduce R&D costs.
3. Translational Medicine and Individualized Medicine
InnoModels' immune co-culture killing model platform also promotes the development of translational medicine and individualized medicine. By providing an experimental platform that is closer to the actual clinical situation, researchers are able to understand the disease mechanism and therapeutic effects more deeply, providing more accurate guidance for clinical diagnosis and treatment.
Conclusion
The launch of InnoModels' immune co-culture killing model platform marks an important leap in immunotherapy research. With its precise technology, wide range of applications and far-reaching impact, the platform provides a solid scientific foundation for research on cancer treatment and immunotherapy. In the future, with the continuous advancement of technology and in-depth expansion of applications, InnoModels Biotechnology will continue to play an important role in life science and pharmaceutical R&D, bringing more hope and possibilities to patients.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司